Filtered By:
Specialty: Internal Medicine
Condition: Heart Attack

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 557 results found since Jan 2013.

LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals
Postgrad Med. 2022 Aug 25. doi: 10.1080/00325481.2022.2117498. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States. Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal risk factor for ASCVD. Current evidence overwhelmingly demonstrates that lowering LDL-C reduces the risk of secondary cardiovascular events in patients with previous myocardial infarction or stroke. There is no lower limit for LDL-C: large, randomized studies and meta-analyses have found continuous benefit and no safety concerns in patients achieving LDL-C levels &...
Source: Postgraduate Medicine - August 25, 2022 Category: Internal Medicine Authors: James Underberg Peter P Toth Fatima Rodriguez Source Type: research

Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France
CONCLUSION: In persons aged 18 to 74 years, adenoviral-based vaccines may be associated with increased incidence of MI and PE. No association between mRNA-based vaccines and the cardiovascular events studied was observed.PRIMARY FUNDING SOURCE: None.PMID:35994748 | DOI:10.7326/M22-0988
Source: Annals of Internal Medicine - August 22, 2022 Category: Internal Medicine Authors: J érémie Botton Marie Joelle Jabagi Marion Bertrand B érangère Baricault J érôme Drouin St éphane Le Vu Alain Weill Paddy Farrington Mahmoud Zureik Rosemary Dray-Spira Source Type: research

Incidence of thromboembolic complications in hospitalized COVID-19 patients in a medical ward in Japan: A single-center retrospective and prospective observational study
Conclusion: Thromboembolic complications of COVID-19 are rare even in severe cases in a medical ward in a Japanese hospital. Further studies are needed to identify severe COVID-19 patients with a higher risk for thromboembolic complications in Japan.
Source: Medicine - August 19, 2022 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Effects of omega-3 fatty acid on major cardiovascular outcomes: A systematic review and meta-analysis
Conclusions: Major cardiovascular events and cardiac death risks could be avoided with the use of omega-3 fatty acid. However, it has no significant effects on the risk of all-cause mortality, myocardial infarction, and stroke.
Source: Medicine - July 29, 2022 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Examining Disparities and Excess Cardiovascular Mortality Before and During the COVID-19 Pandemic
To investigate the patterns and demographics of cardiovascular (CVD) death and subtypes myocardial infarction (MI), stroke, and heart failure (HF) in the pre-COVID-19 era (2018-2019) vs during COVID-19 pandemic (2020-2021) in the United States.
Source: Mayo Clinic Proceedings - July 20, 2022 Category: Internal Medicine Authors: Scott E. Janus, Mohamed Makhlouf, Nicole Chahine, Issam Motairek, Sadeer G. Al-Kindi Tags: Original Article Source Type: research

Study Selection for Reviewing Statins Effects on Low-Density Lipoprotein Cholesterol
To the Editor: We read with interest the systematic review and meta-analysis by Dr Byrne and colleagues. Although the authors conclude that “the absolute benefits of statins are modest,” we identified factors that weaken their argument. Pooling of studies with different clinical contexts may lead to erroneous conclusions. Accordingly, of the 21 randomized clinical trials included, only 6 were secondary prevention trials in which the effect of statins on prognosis was more potent. Furthermore, the specific limitations of the included studies cast doubt on the conclusions. The CORONA (Controlled Rosuvastatin Multinationa...
Source: JAMA Internal Medicine - June 27, 2022 Category: Internal Medicine Source Type: research

Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention
CONCLUSION: SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score.PMID:35695557 | DOI:10.1080/07853890.2022.2083671
Source: Annals of Medicine - June 13, 2022 Category: Internal Medicine Authors: Kangning Han Dongmei Shi Lixia Yang Zhijian Wang Yueping Li Fei Gao Yuyang Liu Xiaoteng Ma Yujie Zhou Source Type: research

The pathogenesis of atherosclerosis
Cardiovascular disease remains the world's leading cause of morbidity and mortality. The myriad of environmental risk factors and predisposing genes leads to a complex multifactorial disease process characterized by a fibro-proliferative and inflammatory process. This results in an activation of cytokines, growth factors and vasoregulatory mechanisms, and leads to intimal thickening and ultimately luminal obstruction. Progressive luminal obstruction or acute rupture of the atherosclerotic lesion can lead to devastating complications such as myocardial infarction, stroke and death.
Source: Medicine - May 27, 2022 Category: Internal Medicine Authors: Michael Mahmoudi Tags: Pathogenesis, risk factors and prevention Source Type: research

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study
CONCLUSION: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.PRIMARY FUNDING SOURCE: Brigham and Women's Hospital and Harvard Medical School.PMID:35605236 | DOI:10.7326/M21-4012
Source: Annals of Internal Medicine - May 23, 2022 Category: Internal Medicine Authors: HoJin Shin Sebastian Schneeweiss Robert J Glynn Elisabetta Patorno Source Type: research